It was a pleasure to catch up with Dr Carl Regillo (Wills Eye Hospital, Philadelphia, PA, USA) about new and emerging neovascular age-related macular degeneration treatments, including the new anti-vascular endothelial growth factor which appear to lead to better outcomes with durability, which is one of the biggest unmet needs in treatment of age-related macular degeneration.
Questions:
- How are new and emerging anti-vascular endothelial growth factor (VEGF) agents providing better outcomes than classic anti-VEGF therapies such as ranibizumab? (0:22)
- What other pathophysiological pathways are being targeted in new and emerging age-related macular degeneration treatments? (2:13)
- What other therapeutic innovations would you like to highlight? (3:20)
The presentation entitled, New and Emerging Neovascular AMD Treatments was presented at the Hawaiian Eye and Retina 2023 meeting, 14–20 January, 2023.
Disclosures: Carl Regillo has served as a consultant for 4DMT, Adverum, Allergan, Annexon, Apellis, Clearside, Curacle, Eyepoint, Genentech, Graybug, Iveric, Janssen, Kodiac, Lineage, Merck, NGM, Novartis, Ocugen, Ocuterra, Ray, RegenXBio, Stealth, Thea, Zeiss, and has received grant/research support from Adverum, Allergan, Annexon, Apellis, Astellis, Curacle, Eyepoint, Genentech, Graybug, Gyroscope, Iveric, Kodiac, Lineage, NGM, Notal, Novartis, Ocugen, Ocuterra, Opthea, Regeneron, RegenXBio.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Lisa Glass.
Filmed as a highlight of Hawaiian Eye and Retina 2023.
Click here for more content from Dr Carl Regillo.
